Brendan P. Eckelman, Chief Scientific Officer, 10% Owner at Inhibrx, Inc. (INBX), sold 78,608 shares at $26.83 ($2.1M) on 2022-12-06, disclosed to the SEC on 2022-12-07.
Open-market sale of $2.1M INBX by Chief Scientific Officer, 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.83 | 20,927 | $561K | 26.3% |
| 2 | $26.83 | 20,927 | $561K | 26.3% |
| 3 | $27.57 | 17,681 | $487K | 22.8% |
| 4 | $27.57 | 17,681 | $487K | 22.8% |
| 5 | $28.46 | 1,392 | $40K | 1.9% |
| Total | $27.19 avg | 78,608 |
| $2.1M |
| 100% |
| Filing → |
| INBX | SELL | 2022-11-02 | $2.7M | — | Filing → |
| INBX | SELL | 2022-10-05 | $2.2M | — | Filing → |
| INBX | SELL | 2022-09-07 | $1.2M | — | Filing → |